Gyre Therapeutics (GYRE) EBT (2010 - 2026)

Gyre Therapeutics (GYRE) has reported EBT for 17 consecutive years, with -$9.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT fell 299.29% year-over-year to -$9.2 million; the TTM figure through Mar 2026 stood at $564000.0 (down 96.33% YoY), while the FY2025 annual figure was $14.4 million, down 37.82% from the prior year.
• EBT eased to -$9.2 million in Q1 2026 per GYRE's latest filing, from -$66000.0 in the prior quarter.
• Across five years, EBT topped out at $51.6 million in Q2 2022 and bottomed at -$100.3 million in Q4 2023.
• Historically, EBT has averaged -$2.3 million across 5 years, with a median of $3.9 million in 2024.
• On a YoY basis, EBT climbed as much as 329.07% in 2023 and fell as far as 339.82% in 2023.
• Gyre Therapeutics' EBT stood at -$22.8 million in 2022, then sank by 339.82% to -$100.3 million in 2023, then soared by 100.77% to $772000.0 in 2024, then tumbled by 108.55% to -$66000.0 in 2025, then slumped by 13895.45% to -$9.2 million in 2026.
• Business Quant data shows GYRE's EBT at -$9.2 million in Q1 2026, -$66000.0 in Q4 2025, and $7.6 million in Q3 2025.